IP Library Granted Patent US 7,718,399
Granted Patent B2
US 7,718,399 · App. 10/576,068 · Granted May 18, 2010

Expression vector for secreting antibody fragment using

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,399
App. No.
10/576,068
Granted
May 18, 2010
Kind
B2
Abstract

A recombinant expression vector capable of expressing and secreting an antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative or E. coli outer membrane protein A (Omp A) signal sequence in the form of a soluble heterozygote protein is used to mass-produce the antibody fragment by culturing a microorganism transformed with the expression vector in a medium and collecting the antibody fragment secreted from the transformed microorganism into the medium.

Claims (23)

1. A method for producing an antibody fragment, comprising the steps of:

1) preparing an expression vector comprising a gene encoding a light chain of the antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative and a gene encoding a heavy chain of the antibody fragment fused with E. coli outer membrane protein A signal sequence, wherein the expression of the genes encoding the light chain and the heavy chain is regulated by a single promoter;

2) transforming a microorganism with the expression vector;

3) culturing the transformed microorganism in a medium; and

4) collecting the antibody fragment from the medium or from the microorganism.

2. The method of claim 1 , wherein the antibody fragment is derived from a chimeric antibody, a humanized antibody or a human antibody.

3. The method of claim 1 , wherein the antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 and scFv.

4. The method of claim 1 , wherein the E. coli thermostable enterotoxin signal sequence derivative has the nucleotide sequence of SEQ ID NO: 17 and the E. coli outer membrane protein A signal sequence has the nucleotide sequence of SEQ ID NO: 23.

5. The method of claim 1 , wherein the promoter is T7 promoter or Tac promoter.

6. The method of claim 1 , wherein the antibody fragment is a fragment of anti-tumor necrosis factor-alpha antibody.

7. The method of claim 1 , wherein the expression vector is pmsoDLHF_N/S.

8. The method of claim 1 , wherein the microorganism is E. coli.

9. The method of claim 8 , wherein the microorganism transformed with the expression vector is E. coli BL21/pmsoDLHF_N/S(HM10924) (KCCM-10513).

10. An expression vector comprising a gene encoding a light chain of the antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative and a gene encoding a heavy chain of the antibody fragment fused with E. coli outer membrane protein A signal sequence, wherein the expression of the genes encoding the light chain and the heavy chain is regulated by a single promoter, and the antibody fragment expressed from the expression vector is secreted into a culture medium where a host carrying the expression vector is cultured or into a periplasmic space of the host.

11. The expression vector of claim 10 , wherein the antibody fragment is derived from a chimeric antibody, a humanized antibody or a human antibody.

12. The expression vector of claim 10 , wherein the antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 and scFv.

13. The expression vector of claim 10 , wherein the E. coli thermostable enterotoxin signal sequence derivative has the nucleotide sequence of SEQ ID NO: 17 and the E. coli outer membrane protein A signal sequence has the nucleotide sequence of SEQ ID NO: 23.

14. The expression vector of claim 10 , wherein the antibody fragment is a fragment of anti-tumor necrosis factor-alpha antibody.

15. The expression vector of claim 10 , wherein the promoter is T7 promoter or Tac promoter.

16. The expression vector of claim 15 , which is pmsoDLHF_N/S.

17. A microorganism transformed with the expression vector of claim 10 .

18. The microorganism of claim 17 , which is E. coli.

19. The microorganism of claim 18 , which is E. coli BL21/pmsoDLHF_N/S(HM10924) (KCCM-10513).

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
CHANGE OF NAME Recorded Jan 7, 2011
From: HANMI PHARM. CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025599/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2006
From: JUNG, SUNG YOUB; KIM, JIN SUN; KWON, SE CHANG; LEE, GWAN SUN
To: HANMI PHARM. CO., LTD.
Reel/Frame 017814/0469 →